Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Abstract Background Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 signalling. The aim of this study was to compare the ef...

Full description

Bibliographic Details
Main Authors: Cem Gabay, Gerd R. Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein, Toshio Kimura, Hubert van Hoogstraten, Susan H. Boklage, Jonathan Sadeh, Neil M. H. Graham, Anita Boyapati
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Sarilumab
Biomarkers
Biologic disease-modifying antirheumatic drug
Cardiovascular risk
Bone remodelling
Online Access:http://link.springer.com/article/10.1186/s13075-020-02163-6

Internet

http://link.springer.com/article/10.1186/s13075-020-02163-6

Similar Items